Concerning parity for the use of non-opioid pain management drugs, and, in connection therewith, making an appropriation.
Summary
SB26-006 requires health insurance carriers that cover prescription drugs to treat FDA-approved non-opioid pain management drugs more favorably in utilization review and cost-sharing than current law often does. For chronic or acute pain, the bill says prior authorization and step therapy for a non-opioid pain drug cannot be more restrictive than the least restrictive requirements applied to opioid drugs used for the same purpose. It also requires carriers to make at least one clinically appropriate non-opioid alternative available for each opioid prescription drug and to keep patient cost-sharing, copayments, and deductibles for non-opioid pain drugs no higher than those for comparable opioid drugs.
The bill also directs the Department of Health Care Policy and Financing to ensure similar parity in the Medicaid-related context it oversees, so that utilization review for non-opioid pain drugs is no more restrictive than the least restrictive review applied to opioid pain drugs. The measure is framed as a prescription drug benefit and pain-management policy change, and it excludes group benefit plans issued under the State Employee Group Benefits Act from the new subsection.
The overall sentiment reflected in the bill’s structure and sponsorship is supportive of expanding access to non-opioid pain treatment and reducing barriers to safer alternatives to opioids. The bipartisan sponsorship suggests the measure was not viewed as highly partisan, and the bill ultimately passed and was signed by the governor.
The main point of contention is likely the impact on insurers and plan administrators, who would need to adjust prior authorization, step therapy, formulary design, and cost-sharing structures to comply with parity requirements. Another possible issue is the scope of the mandate—particularly whether requiring at least one clinically appropriate non-opioid alternative for each opioid drug could limit carrier flexibility or increase administrative and benefit costs. The exclusion for state employee plans also indicates that public-plan coverage rules were treated differently from the broader market.
Impact
SB26-006 amends Colorado insurance law at section 10-16-145.5 to add a new subsection requiring parity between non-opioid pain management drugs and opioid drugs in utilization review and patient cost-sharing. It affects health insurance carriers that provide prescription drug benefits by limiting prior authorization and step therapy restrictions on FDA-approved non-opioid pain drugs, and by requiring comparable or lower out-of-pocket costs for those drugs. It also directs the Department of Health Care Policy and Financing to apply similar standards in the programs it administers, while expressly excluding State Employee Group Benefits Act plans from the new requirement.
Sentiment
The bill appears to have been received positively overall, with bipartisan sponsorship and no recorded committee or floor controversy in the provided materials. Its purpose—encouraging access to non-opioid pain management options and reducing opioid reliance—suggests broad policy support. The fact that it was signed by the governor indicates it advanced successfully through the legislative process without evident opposition strong enough to stop enactment.
Contention
The likely areas of contention are operational and fiscal rather than ideological: insurers may object to mandated parity in prior authorization, step therapy, and cost-sharing because it can constrain formulary management and potentially increase plan costs. Health plans and administrators may also question how to determine the “least restrictive” opioid utilization review standard and what qualifies as a “clinically appropriate” non-opioid alternative. The explicit exclusion of state employee group benefit plans suggests that coverage mandates for public employee plans were treated differently, which may reflect policy or budget concerns.